Tracks survival of adults with unresectable liver cancer in routine care
Observes how long adults with inoperable liver cancer survive under usual treatment in Asia Pacific.
Key facts
- Who runs it
- Humanity & Health Medical Group Limited
- Where
- Hong Kong, Hong KongSee the siteAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- The Overall Survival of Patients With Unresectable HCC in Real-life
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 16 Jul 2018
- Planned end
- 31 Dec 2025
- Type of study
- Observational
- Record updated
- 24 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults diagnosed with hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. It follows how long they live in routine care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Hepatocellular carcinoma that cannot be removed by surgery (unresectable)
Main reasons for not taking part
- Not willing to take part
- Not willing to give written informed consent
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients with a diagnosis of unresectable hepatocellular carcinoma
- Able to comprehend and provide written informed consent in accordance with institutional guidelines
Who cannot take part
- Patients not willing to participate and/or give their written informed consent
Where in Hong Kong
Also in 2 other countries, 2 sites
- Humanity & Health Medical Group LimitedHong Kong, Hong KongContact: George Lau, MDTaking people
About the trial
What the trial wants to find out
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China).
Read full original descriptionShow less
The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region
- Plain-language title
- Tracks survival of adults with unresectable liver cancer in routine careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 March 2025